Parvoduk

RSS

live attenuated Muscovy duck parvovirus

Authorised
This medicine is authorised for use in the European Union.

Overview

This is a summary of the European public assessment report. Its purpose is to explain how the assessment done by the Committee for Medicinal Products for Veterinary Use (CVMP) on the basis of the documentation provided, led to the recommendations on the conditions of use.

This summary cannot replace a face-to-face discussion with your veterinarian. If you need more information about your animal’s medical condition or treatment, contact your veterinarian. If you want more information on the basis of the CVMP recommendations, read the scientific discussion (also part of the EPAR).

This EPAR was last updated on 09/12/2015

Authorisation details

Product details
Name
Parvoduk
Agency product number
EMEA/V/C/002740
Active substance
live attenuated Muscovy duck parvovirus
International non-proprietary name (INN) or common name
live attenuated Muscovy duck parvovirus
Species
Ducks
Anatomical therapeutic chemical veterinary (ATCvet) codes
QI01BD03
Publication details
Marketing-authorisation holder
Merial
Revision
1
Date of issue of marketing authorisation valid throughout the European Union
11/04/2014
Contact address
29 avenue Tony Garnier
69007 Lyon
France

Product information

04/12/2015 Parvoduk - EMEA/V/C/002740 - IB/0002

Contents

  • Annex I - Summary of product characteristics
  • Annex IIA - Manufacturing-authorisation holder responsible for batch release
  • Annex IIB - Conditions of the marketing authorisation
  • Annex IIIA - Labelling
  • Annex IIIB - Package leaflet

Please note that the size of the above document can exceed 50 pages.

You are therefore advised to be selective about which sections or pages you wish to print.

Pharmacotherapeutic group

  • Immunologicals for ducks
  • live viral vaccines against duck parvovirus

Therapeutic indication

Active immunisation of ducks to prevent mortality1 and to reduce weight loss and lesions of duck parvovirosis and Derzsy's disease.


1In absence of maternally derived antibodies.

Assessment history

How useful was this page?

Add your rating